October 25, 2019

The Supreme Court’s Albrecht Decision: Unclear Implications for Adverse Reaction Warnings

Elie Biel authored an article for Minnesota Physician regarding a decision by the Supreme Court of the United States to remand a pharmaceutical labeling case to a lower court for future proceedings. The article discusses the litigation surrounding the prescription drug Fosamax, with a focus on the whether the state-based failure-to-warn claim was barred by federal law. Biel further discusses the long-term implications of the decision, highlighting potential areas of concern for future litigants.
Full Article

Related Legal Services

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.